Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardinal given class I notice for Alaris recall

This article was originally published in Clinica

Executive Summary

Cardinal Health has again reported faults related to its Alaris electronic infusion pumps, prompting a class I recall notification from the FDA. The agency gave the product the highest possible recall classification after the Dublin, Ohio-based company reported five problems with the system including issues with the occlusion warning message, syringe volume warning message, electrostatic discharge protection security and fluid ingress tubing. The FDA said that these faults may result in serious injury or death caused by over- or under-infusion of medication. Cardinal previously recalled 200,000 Alaris pumps in January 2008 after a defect in the device’s spring was linked to two patient deaths (see Clinica No 1289, p 14). In February 2007, Cardinal reached an agreement with the FDA regarding corrective action over oversensitive keypads used with its Alaris SE line of infusion pumps (see Clinica No 1244, p 7).

You may also be interested in...



Alere aided by professional diagnostics sales in fourth quarter

Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.

Integra and Stout to work on expandable interbody device

Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.

Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials

Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals

Topics

UsernamePublicRestriction

Register

MT043997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel